Regulatory Updates

Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses

FDA · dry eyes · 5 min

EMEA 2026 Life Sciences Report: Key Market Shifts for Pharma BD and Investors

4 min

Federal Court Litigation on Reproductive Health: Rare Disease Implications

FDA · rare disease · 5 min

EC nod for Chiesi Lojuxta for pediatric HoFH: what it means for pharma

European Commission (EC) · rare disease · 5 min

European Cancer Guidelines Add Delcath Liver Therapy for Eye Melanoma

oncology · 5 min

Maersk Europe Market Update June 2026: Key Changes for Pharma Supply Chains

4 min

Regulatory round-up: 2 February 2026 – EMA opinions, FDA approvals, and what they mean for pharma

FDA · 4 min

FDA Voucher Program Pause Urged: Rare Disease Policy Analysis

FDA · rare disease · 5 min

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates

myasthenia gravis · 4 min

MFN Drug Pricing Reshapes International Life Sciences Licensing Deals

4 min

India-Oman CEPA Fast-Tracks Drug Approvals, Cuts Export Barriers for Pharma

4 min

Moderna Stock Rises as EMA Committee Backs New RSV Vaccine: Key Implications for Investors and BD Teams

EMA · 5 min